Welcome to our dedicated page for Diamedica Therapeutics news (Ticker: DMAC), a resource for investors and traders seeking the latest updates and insights on Diamedica Therapeutics stock.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical-stage biopharmaceutical company whose news flow centers on the development of DM199, a recombinant KLK1 protein candidate for preeclampsia, fetal growth restriction and acute ischemic stroke. Company updates frequently highlight progress in its clinical trials, regulatory interactions and financing activities that support these programs.
Investors following DMAC news can expect detailed reports on the Phase 2 investigator-sponsored trial of DM199 in preeclampsia, including interim data on blood pressure reduction, uterine artery blood flow and placental transfer findings. DiaMedica also issues news about the multi-part design of this trial, expansion cohorts, and plans to evaluate DM199 in women with early-onset fetal growth restriction.
Another major news theme is the ReMEDy2 Phase 2/3 trial in acute ischemic stroke, where DiaMedica provides enrollment updates and guidance on the timing of interim analyses. Regulatory milestones, such as the in-person pre-IND meeting with the U.S. Food and Drug Administration for a planned U.S. Phase 2 preeclampsia study and related non-clinical study requirements, are also covered in company press releases.
DiaMedica’s news feed additionally includes quarterly financial results, descriptions of its cash runway in relation to planned clinical studies, private placements and at-the-market offering arrangements. Corporate developments, such as participation in healthcare investor conferences, inducement equity grants and executive appointments in clinical leadership roles, appear regularly. For readers tracking DMAC, this news page offers a consolidated view of clinical, regulatory, financial and corporate announcements related to the company’s efforts in preeclampsia, fetal growth restriction and acute ischemic stroke.
DiaMedica Therapeutics (Nasdaq: DMAC) has appointed Dr. Julie Krop as its new Chief Medical Officer, effective immediately. Dr. Krop, who brings over 20 years of experience in strategic physician executive leadership, replaces Dr. Lorianne Masuoka, who resigned for personal reasons.
Dr. Krop joins from PureTech Health where she served as CMO and Head of Development. Her extensive experience includes leadership roles at Freeline Therapeutics, AMAG Pharmaceuticals, Vertex Pharmaceuticals, and Pfizer. Notably, she has specific experience in preeclampsia drug development, which aligns with DiaMedica's focus on developing DM199 for preeclampsia and acute ischemic stroke treatments.
DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, will announce its second quarter 2025 financial results on August 12, 2025, after market close. The company will host a conference call on August 13, 2025, at 8:00 AM ET to discuss the results and provide a business update.
DiaMedica focuses on developing novel treatments for preeclampsia and acute ischemic stroke, with its lead candidate DM199 being the first pharmaceutically active recombinant form of the KLK1 protein. This therapeutic has established applications in Asia for treating acute ischemic stroke, preeclampsia, and other vascular diseases.
DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, has completed a $30.1 million private placement by selling approximately 8.6 million common shares at $3.50 per share. After expenses, the company received net proceeds of $29.9 million.
The company's pro forma cash position, including the placement proceeds, would have been $67.2 million as of March 31, 2025, up from $37.3 million. Notably, significant participation came from related parties, with $16.8 million invested by non-management related parties. Major investors included Thomas von Koch (increasing stake to 16.2%), Trill AB (increasing to 13.1%), and Richard Jacinto II (position adjusting to 9.6%).
DiaMedica Therapeutics (Nasdaq: DMAC) has secured a $30.1 million private placement of common shares at $3.50 per share, with participation from current investors. The company will issue 8,606,426 common shares, with the transaction expected to close around July 23, 2025.
The funding will support DiaMedica's operations for over two years, focusing on their clinical program for preeclampsia and fetal growth restriction treatments. Key milestones include submitting an IND application in the United States and conducting a Phase 2b study to evaluate DM199 in both indications, pending approval.
The private placement qualifies as a related party transaction under Canadian securities regulations but is exempt from valuation and minority shareholder approval requirements as it represents less than 25% of the company's market capitalization.
DiaMedica Therapeutics (Nasdaq: DMAC) announced positive interim Phase 2 results for DM199 (rinvecalinase alfa) in treating preeclampsia. The study demonstrated statistically significant blood pressure reductions, with the highest dose cohort showing decreases of -35 mmHg in systolic and -15 mmHg in diastolic blood pressure (p<0.05).
Key findings include no placental transfer of DM199 and a 13.2% reduction in uterine artery pulsatility index (p=0.0003), suggesting improved placental blood flow. The treatment was generally safe with only mild adverse events reported. The study enrolled patients with mean baseline systolic/diastolic blood pressure of 165/102 mmHg at 37 weeks gestation.
The company will proceed with the dose expansion cohort (Part 1b) and initiate enrollment in the fetal growth restriction cohort (Part 3), potentially offering the first pharmacological treatment for preeclampsia in the US and Europe.
DiaMedica Therapeutics (NASDAQ:DMAC), a clinical-stage biopharmaceutical company, announced its upcoming inclusion in the Russell 2000® and Russell 3000® Indexes, effective after market close on June 27, 2025. This milestone enhances the company's visibility among institutional investors, as these indexes are widely used as benchmarks for investment strategies.
The company recently hosted a preeclampsia webinar featuring key opinion leaders discussing their lead candidate DM199, the first pharmaceutically active recombinant form of the KLK1 protein. DiaMedica expects to announce Phase 2 top-line results by mid-July for their preeclampsia treatment program.
DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing treatments for preeclampsia and acute ischemic stroke, has announced its participation in the Jefferies Global Healthcare Conference. The event will take place in New York City from June 3-5, 2025. President and CEO Rick Pauls and Chief Business Officer Dave Wambeke will deliver a presentation on June 4, 2025, at 12:50 PM Eastern Time. The management team will also be available for one-on-one meetings with investors to discuss the company's strategy, recent developments, and future outlook.
DiaMedica Therapeutics (NASDAQ: DMAC) announced a virtual Key Opinion Leader (KOL) event scheduled for May 28, 2025, at 8:00 AM ET. The webinar will feature prominent experts including Prof. Stephen Tong, Prof. Susan Walker, and Prof. Baha Sibai, who will discuss preeclampsia treatment landscape and the design of DM199's Phase 2 clinical trial.
The event will focus on DM199 (Rinvecalinase Alfa), the company's novel treatment for preeclampsia, a life-threatening pregnancy-associated vascular disorder with no approved therapeutics. DM199 works by enhancing the body's natural ability to produce nitric oxide, prostacyclin, and endothelium-derived hyper polarizing factor, potentially lowering blood pressure, improving endothelial health, and enhancing perfusion to maternal organs and placenta.
DiaMedica Therapeutics (NASDAQ: DMAC) announced a poster presentation at the 11th European Stroke Organisation Conference (ESOC 2025) in Helsinki, Finland from May 21-23, 2025. The poster (P-704) will present safety and clinical outcomes data from the ReMEDy2 study, a pivotal phase 2/3 trial of DM199 (rinvecalinase alfa) in acute ischemic stroke patients.
Dr. John J. Volpi, a ReMEDy2 trial Scientific Advisory Board Member, will be available on May 22, 2025, to answer questions about the poster titled "Assessing Safety and Clinical Outcomes of Rinvecalinase Alfa (DM199) in Acute Ischemic Stroke Patients Pre-treated with Intravenous Thrombolytics Only." The company will also exhibit at booth D4.1.